Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).

被引：1
|
作者：
Sim, Hao-Wen
Barnes, Elizabeth
Lwin, Zarnie
Rosenthal, Mark
Wheeler, Helen
Koh, Eng-Siew
Foote, Matthew C.
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Simes, John
Khasraw, Mustafa
机构：
[1] St Vincents Hosp Sydney, Kinghorn Canc Ctr, Sydney, NSW, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[3] Dept Med Oncol, Brisbane, Qld, Australia
[4] Royal Melbourne Hosp, Parkville, Vic, Australia
[5] Royal North Shore Hosp, Dept Oncol, St Leonards, NSW, Australia
[6] Liverpool Hosp, Liverpool, Merseyside, Australia
[7] Univ Queensland, Princess Alexandra Hosp, Brisbane, Qld, Australia
[8] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[9] COGNO Consumer Advisory Panel, Sydney, NSW, Australia
[10] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[11] Univ Sydney, Royal North Shore Hosp, St Leonards, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2042
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902)
    Galanis, Evanthia
    Anderson, S. Keith
    Miller, C. Ryan
    Sarkaria, Jann Nagina
    Jaeckle, Kurt A.
    Buckner, Jan C.
    Ligon, Keith L.
    Ballman, Karla V.
    Moore, Dennis Frederic
    Ahluwalia, Manmeet Singh
    Lee, Eudocia Quant
    Gerstner, Elizabeth Robins
    Lesser, Glenn Jay
    Prados, Michael
    Grossman, Stuart A.
    Giannini, Catarina
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma.
    Verschaeve, V.
    D'Hondt, L. A.
    Verbeke, L. M. J.
    Van Fraeyenhove, F.
    Du Four, S.
    Duerinck, J.
    Neyns, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma
    Werlenius, Katja
    Stragliotto, Giuseppe
    Strandeus, Michael
    Blomstrand, Malin
    Caren, Helena
    Jakola, Asgeir S.
    Rydenhag, Bertil
    Dyregaard, Dorte
    Dzhandzhugazyan, Karine N.
    Kirkin, Alexei F.
    Raida, Martin K.
    Smits, Anja
    Kinhult, Sara
    NEURO-ONCOLOGY ADVANCES, 2021, 3 (01)
  • [44] Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A. Quinn
    Sara Xiaoyin Jiang
    David A. Reardon
    Annick Desjardins
    James J. Vredenburgh
    Allan H. Friedman
    John H. Sampson
    Roger E. McLendon
    James E. Herndon
    Henry S. Friedman
    Journal of Neuro-Oncology, 2009, 95 : 393 - 400
  • [45] Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Quinn, Jennifer A.
    Jiang, Sara Xiaoyin
    Reardon, David A.
    Desjardins, Annick
    Vredenburgh, James J.
    Friedman, Allan H.
    Sampson, John H.
    McLendon, Roger E.
    Herndon, James E., II
    Friedman, Henry S.
    JOURNAL OF NEURO-ONCOLOGY, 2009, 95 (03) : 393 - 400
  • [46] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients
    Sarkaria, J. N.
    Galanis, E.
    Wu, W.
    Giannini, C.
    Jaeckle, K. A.
    Doyle, L.
    Uhm, J.
    Brown, P.
    Dietz, A. B.
    Buckner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] BEVACIZUMAB (BV) IN COMBINATION TO TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): A PHASE 2 TRIAL
    Desjardins, Annick
    Reardon, David A.
    Peters, Katherine B.
    Herndon, James
    Kirkpatrick, John
    Gururangan, Sridharan
    Sampson, John H.
    Friedman, Allan H.
    Friedman, Henry
    Vredenburgh, James J.
    NEURO-ONCOLOGY, 2009, 11 (05) : 634 - 634
  • [48] Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
    Mason, Warren P.
    Kesari, Santosh
    Stupp, Roger
    Aregawi, Dawit Gebremichael
    Piccioni, David Eric
    Roth, Patrick
    Desjardins, Annick
    Reich, Steven D.
    Casadebaig, Marie-Laure
    Elias, Ileana
    Winograd, Benjamin
    Levin, Nancy
    Bota, Daniela Annenelie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Mature results of a phase I/IIA trial of the integrin inhibitor cilengitide (EMD121974) added to standard concomitant and adjuvant temozolomide and radiotherapy (TMZ/RT) for newly diagnosed glioblastoma (GBM)
    Stupp, Roger
    Goldbrunner, Roland
    Neyns, Bart
    Schlegel, Uwe
    Clement, Paul
    Grabenbauer, Gerhard
    Hegi, Monika
    Nippgen, Johannes
    Picard, Martin
    Weller, Michael
    NEURO-ONCOLOGY, 2007, 9 (04) : 517 - 517
  • [50] Radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus radiotherapy alone for newly diagnosed glioblastoma (GBM): Overall results and recursive partitioning analysis (RPA) of a phase III randomized trial of the EORTC brain tumor and radiotherapy groups and the NCIC clinical trial group
    Mirimanoff, R
    Mason, W
    Kortmann, R
    Van den Bent, M
    Fisher, B
    Taphoorn, M
    Reni, M
    Curschmann, J
    Villa, S
    Cairncross, G
    Gorlia, T
    Stupp, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S162 - S162
12345